Enveda Secures $311M at $2B Valuation for Nature-Derived AI Drugs

Biotechnology company Enveda has secured $311 million in a Series E crossover financing round, elevating its post-money valuation to $2 billion. The transaction, led by Catalio Capital Management with participation from prominent investment firms such as ICONIQ, Lightspeed, Durable Capital Partners, T. Rowe Price Investment Management, and Surveyor Capital, effectively doubles the corporate valuation achieved by the company twelve months prior. This substantial influx of institutional capital brings Enveda's total funding to more than $845 million accumulated over the past six years.

Founded in 2019 by Viswa Colluru, a former early employee at Recursion Pharmaceuticals, Enveda operates on the foundational thesis that the planet's vast biological diversity holds untapped chemical blueprints for novel therapeutics. Rather than synthesizing molecular entities entirely from scratch in a chemical laboratory, the enterprise utilizes machine learning, computational metabolomics, and advanced analytical methods to decode complex chemistry found within botanical and microbial organisms. Through its specialized computational engine, named the PRISM platform, Enveda translates ancient natural chemistry into drug candidates suitable for rigorous clinical progression.

Advancing Pipeline Assets Through Human Clinical Trials

To date, Enveda has generated a portfolio of 17 therapeutic candidates, with three distinct molecules already undergoing human clinical testing. While artificial intelligence has not yet yielded an FDA-approved medicine anywhere in the pharmaceutical sector, Enveda is among a select cohort of tech-enabled biotechs demonstrating measurable clinical momentum with computational molecules.

The newly acquired $311 million is designated to accelerate several key therapeutic assets toward mid-stage and late-stage clinical evaluations:

• ENV-308: An oral obesity candidate described as an exercise-in-a-tablet mechanism and weight loss maintenance therapy designed to sustain body mass reduction after discontinuation of GLP-1 treatments. The asset demonstrated clinical tolerability in a Phase 1 clinical trial readout completed in August.
• ENV-294: A therapeutic candidate targeting severe inflammatory skin conditions that successfully reduced disease severity in an early-stage clinical trial for atopic dermatitis, as documented in clinical results released in July.
• ENV-6946: A clinical asset formulated for inflammatory bowel disease, slated to move through mid-stage human testing with the support of the Series E capital.
• PRISM Platform and Early Pipeline: Further technological refinement of Enveda's core artificial intelligence architecture to systematically advance earlier preclinical assets targeting complex inflammatory and metabolic disorders.

Enveda has confirmed that expanded clinical trials targeting broader patient cohorts and additional therapeutic indications are scheduled to commence in the coming months, marking an operational shift toward late-phase drug development.

We started Enveda on a different premise: the most reliable source of new medicines is the chemistry that living things have been refining for billions of years, and AI finally lets us read it.

Bridging Computational Biology and Industrial Clinical Validation

The participation of specialized healthcare crossover investors alongside traditional technology venture funds signals deliberate financial alignment for a potential future initial public offering. Lead backer Catalio Capital Management has previously deployed capital into high-profile life sciences enterprises, including obesity-focused biotech Kailera Therapeutics and computational antibody designer BigHat Biosciences. For institutional backers, Enveda represents an effort to de-risk algorithmic discovery by backing platforms that own fully integrated internal pipelines rather than functioning purely as outsourced software service providers.

With two novel molecules having shown their early potential in people, this financing lets us build the company those results deserve, one that can carry its own medicines from discovery through late-stage development and do it faster and at lower cost than the industry has come to accept.

For biotechnology organizations, pharmaceutical companies, and research institutions evaluating artificial intelligence strategies, Enveda's capital milestone highlights a structural shift in how computational drug discovery programs are capitalized and measured. Rather than relying on early predictive benchmarks or algorithmic validation alone, life sciences organizations must increasingly substantiate their technological claims through verifiable Phase 1 and Phase 2 clinical readouts in human subjects. For corporate strategy teams, partnerships in the natural products sector are re-emerging as viable competitive alternatives to purely synthetic screening libraries, provided they are supported by end-to-end computational identification platforms.